title: [Bone marrow relapse in high-risk pediatric patients with acute lymphoblastic leukemia: a comparison of relapse times and initial clinical features of patients on different protocols. Children's Cancer and Leukemia Study group (CCLSG)].
abstract: To clarify the efficacy of modern intensive chemotherapy for ALL patients with unfavorable features, we compared the time to failure and initial clinical features of children who relapsed in the bone marrow or combined sites, as documented by early CCLSG studies (H811 and H851; 1981-1987) and later studies (H874 and H/HH911; 1987-1993) concerning high-risk ALL patients. In the later studies patients outcomes with new intensive regimens employing early intensification and reinduction therapy were apparently better than those of patients in the early studies with conventional regimens. When we compared the number of relapsed patients based on duration of first remission, we found that the improved outcomes for patients in the later studies were due to a decrease in the number who relapsed 7-36 months after the start of treatment (intermediate relapse), and that the percentage of those who relapsed within the first 6 months of therapy (early relapse) was higher. Patients with high initial WBC counts tended to relapse much earlier than those with low initial WBC counts. However, in the later studies, patients with high WBC counts often relapsed after the termination of therapy (late relapse). These results suggest that the intensive chemotherapy regimens used in the later studies can prevent the development of drug resistant leukemic clones, except in extremely high-risk patients likely to relapse within the first 6 months of therapy.
authors.forename: M
authors.initials: M
authors.lastname: Tsurusawa
authors.forename: N
authors.initials: N
authors.lastname: Katano
authors.forename: T
authors.initials: T
authors.lastname: Hirota
authors.forename: S
authors.initials: S
authors.lastname: Koizumi
authors.forename: K
authors.initials: K
authors.lastname: Asami
authors.forename: M
authors.initials: M
authors.lastname: Chin
authors.forename: S
authors.initials: S
authors.lastname: Ota
authors.forename: T
authors.initials: T
authors.lastname: Kawakami
authors.forename: Y
authors.initials: Y
authors.lastname: Hatae
authors.forename: I
authors.initials: I
authors.lastname: Sekine
authors.forename: A
authors.initials: A
authors.lastname: Iwai
authors.forename: K
authors.initials: K
authors.lastname: Anami
authors.forename: K
authors.initials: K
authors.lastname: Nishi
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Yatabe
authors.forename: K
authors.initials: K
authors.lastname: Kawakami
authors.forename: K
authors.initials: K
authors.lastname: Gushi
authors.forename: S
authors.initials: S
authors.lastname: Yokota
authors.forename: T
authors.initials: T
authors.lastname: Gusiken
authors.forename: A
authors.initials: A
authors.lastname: Kikuta
authors.forename: J
authors.initials: J
authors.lastname: Mimaya
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: M
authors.initials: M
authors.lastname: Iga
authors.forename: T
authors.initials: T
authors.lastname: Fujimoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019046:Bone Marrow Neoplasms / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012306:Risk; D013997:Time Factors